These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 27463974)

  • 41. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease.
    Parnetti L; Chiasserini D
    Biomark Med; 2011 Aug; 5(4):479-84. PubMed ID: 21861669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease.
    Isobe C; Murata T; Sato C; Terayama Y
    Life Sci; 2005 Aug; 77(15):1836-43. PubMed ID: 15935398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
    Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
    [TBL] [Abstract][Full Text] [Related]  

  • 45. TAU haplotype and the Saitohin Q7R gene polymorphism do not influence CSF Tau in Alzheimer's disease and are not associated with frontotemporal dementia or Parkinson's disease.
    Johansson A; Zetterberg H; Håkansson A; Nissbrandt H; Blennow K
    Neurodegener Dis; 2005; 2(1):28-35. PubMed ID: 16909000
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biomarkers in Alzheimer's disease drug development.
    Cummings JL
    Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biomarkers in Neurodegenerative Diseases.
    Jeromin A; Bowser R
    Adv Neurobiol; 2017; 15():491-528. PubMed ID: 28674995
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment.
    Hu WT; Chen-Plotkin A; Arnold SE; Grossman M; Clark CM; Shaw LM; Pickering E; Kuhn M; Chen Y; McCluskey L; Elman L; Karlawish J; Hurtig HI; Siderowf A; Lee VM; Soares H; Trojanowski JQ
    Acta Neuropathol; 2010 Jun; 119(6):669-78. PubMed ID: 20232070
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.
    Leaver K; Poston KL
    Neuropsychol Rev; 2015 Dec; 25(4):411-23. PubMed ID: 26626621
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease.
    Baldeiras I; Santana I; Leitão MJ; Ribeiro MH; Pascoal R; Duro D; Lemos R; Santiago B; Almeida MR; Oliveira CR
    J Neurol Sci; 2015 Nov; 358(1-2):308-16. PubMed ID: 26388316
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.
    Blennow K; Zetterberg H
    Med Clin North Am; 2013 May; 97(3):369-76. PubMed ID: 23642576
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis.
    Luo X; Shi H; Hou L; Zhong X; Chen X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chen J; Fang Y; He H; Ning Y
    Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preliminary study of hsa-miR-626 change in the cerebrospinal fluid of Parkinson's disease patients.
    Qin LX; Tan JQ; Zhang HN; Tang JG; Jiang B; Shen XM; Tang BS; Wang CY
    J Clin Neurosci; 2019 Dec; 70():198-201. PubMed ID: 31492481
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Defining and disease-modifying therapy for the preclinical stages of Alzheimer's disease].
    Sakurai H; Hanyu H
    Nihon Rinsho; 2016 Mar; 74(3):438-41. PubMed ID: 27025083
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of cerebrospinal fluid proteins as potential biomarkers for early stage Parkinson's disease diagnosis.
    Dos Santos MCT; Scheller D; Schulte C; Mesa IR; Colman P; Bujac SR; Bell R; Berteau C; Perez LT; Lachmann I; Berg D; Maetzler W; Nogueira da Costa A
    PLoS One; 2018; 13(11):e0206536. PubMed ID: 30383831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers.
    Paolini Paoletti F; Gaetani L; Parnetti L
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32092971
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease.
    Pirttila T; Mehta PD; Frey H; Wisniewski HM
    Neurobiol Aging; 1994; 15(3):313-7. PubMed ID: 7936055
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation.
    Shi M; Movius J; Dator R; Aro P; Zhao Y; Pan C; Lin X; Bammler TK; Stewart T; Zabetian CP; Peskind ER; Hu SC; Quinn JF; Galasko DR; Zhang J
    Mol Cell Proteomics; 2015 Mar; 14(3):544-55. PubMed ID: 25556233
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.
    Arnerić SP; Batrla-Utermann R; Beckett L; Bittner T; Blennow K; Carter L; Dean R; Engelborghs S; Genius J; Gordon MF; Hitchcock J; Kaplow J; Luthman J; Meibach R; Raunig D; Romero K; Samtani MN; Savage M; Shaw L; Stephenson D; Umek RM; Vanderstichele H; Willis B; Yule S
    J Alzheimers Dis; 2017; 55(1):19-35. PubMed ID: 27662307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.